• Accession Date:

  03/25/2026
• First Sale Date:

  03/11/2026
• Offering Amount:

  $33,515,000
• Amount Sold:

  $15,890,000
• Amount Remaining:

  $17,625,000
• Exemptions:

  Rule 506
• Security Type(s):

  Equity, An interest in 50% of proceeds received (after deducting fees) from the potential future sale of a Rare Pediatric Disease Priority Review Voucher, to the extent received from the U.S. FDA in connection with the Company's laromestrocel program for HLHS.
• Sales Clarification:

  Total offering amount: purchase price of shares of Class A common stock, Series A Preferred Stock, an interest in future proceeds from a potential future PRV sale, proceeds due to Company assuming cash exercise of all warrants issued to placement agent

Notices found in EFD